Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Marimed Q3 2026 Results: Net Loss of $3.5M, Loss Widens

MariMed Inc. reported revenue of $44.2 million for the third quarter of 2026, a 9% increase year-over-year, though it recorded a net loss of $3.5 million due to high income tax provisions and interest expenses. The company's balance sheet shows $10.4 million in cash and a total of 405,996,010 common shares outstanding as of November 10, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue44.240.8
Gross profit17.216.4
Profit before tax-0.7-0.2
Net income-3.5-2.9
EPS (diluted, $ a share)$-0.01$-0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+8.5%
Gross margin38.8%
Operating margin2.8%
Source

10-Q filed with the SEC, OTC: MRMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Marimed Inc.: key numbers

Share price
$0.0626Close, Nov 16
Market cap
$25.4M
Shares outstanding
406MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Marimed Inc.

All →
6:10 AM ET 8-K
Financial Results

Marimed Financial Results

MariMed Inc. reported record third-quarter 2026 revenue of $44.2 million, a year-over-year increase driven by growth in both wholesale and retail segments. Despite the revenue growth, the company reported a GAAP net loss of $3.5 million as it continues to execute its 'Expand the Brand' strategy and navigate broader market conditions.

Term
Q3 2026

“I’m pleased to report that the momentum we built earlier this year extended through the third quarter. Wholesale and retail revenue both grew sequentially and year over year, and total revenue reached another record for MariMed. Adjusted EBITDA improved from the prior quarter, and we again generated positive cash flow from operations, ending the quarter in our strongest position in more than two years.”

Jon Levine, MariMed’s Chief Executive Officer
4:13 PM ET 8-K
Reverse Stock Split

Marimed Reverse Stock Split

MariMed stockholders approved a proposal to authorize the board of directors to effect a reverse stock split of its common stock at a ratio between 1-for-50 and 1-for-100. The board retains the discretion to determine the final ratio and timing, or to abandon the split entirely, with the primary goal of potentially meeting listing requirements for a U.S. national securities exchange.

4:07 PM ET 8-K
Reverse Stock Split

Marimed Reverse Stock Split

MariMed Inc. has filed a definitive proxy statement for a special meeting of stockholders to seek approval for a reverse stock split at a ratio between 1-for-50 and 1-for-100. The move is intended to increase the share price to satisfy listing requirements for a potential move to a major U.S. national securities exchange. The special meeting is scheduled for October 28, 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.